Hong Kong Pharmaceuticals & Biotech Profitable Climbers

Biocytogen Pharmaceuticals (Beijing)

Market Cap: HK$55.5b

A biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally.

WuXi XDC Cayman

Market Cap: HK$70.3b

An investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally.

XtalPi Holdings

Market Cap: HK$31.0b

Operates as a research platform company in Mainland China, the United States, and internationally.

Sihuan Pharmaceutical Holdings Group

Market Cap: HK$7.9b

An investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical and medical aesthetic products in the People’s Republic of China, the United States, and internationally.

Innovent Biologics

Market Cap: HK$156.6b

A biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, Europe, and internationally.

SSY Group

Market Cap: HK$6.9b

An investment holding company, researches, develops, manufactures, trades, and sells various pharmaceutical products to hospitals and distributors in the People’s Republic of China and internationally.

China Medical System Holdings

Market Cap: HK$29.3b

An investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China.

Viva Biotech Holdings

Market Cap: HK$2.6b

An investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide.